Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Signs Exclusive Agreement with Theraclion to Distribute Echopulse® HIFU Product in France
EDAP to Market Echotherapy for ablation of breast fibroadenomas and benign thyroid nodules LYON, France , October 9, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the signature of an Agreement with French HIFU Company Theraclion, to exclusively
View HTML
Toggle Summary EDAP Announces FDA Clearance of its Ablatherm-Fusion® device
LYON, France , October 4, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced FDA approval of its Ablatherm-Fusion device enabling a more precise method for targeting of diagnosed areas within the prostate. Marc Oczachowski , Chief Executive Officer of
View HTML
Toggle Summary EDAP Announces Opening of two New Ablatherm-HIFU Excellence Urology Centers in the U.S.
    University of Chicago Medicine - Dr. A. Shalhav, Chair of Urology Surgery and Director of Robotic Surgery  Vituro Health LLC - Dr. S. Scionti , Medical Director and Director of The Scionti Prostate Center in Sarasota, FL LYON, France , September 19, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global
View HTML
Toggle Summary EDAP Announces Filing of New 510(k) Application for Focal One® Device
510(k) Includes New Clinical Data to Support EDAP's File LYON, France , September 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a new 510(k) application for its Focal One device, including an updated clinical section
View HTML
Toggle Summary EDAP Partners with Leading US HIFU provider, Vituro Health Adds Ablatherm Robotic HIFU
  Dr. S. Scionti , Medical Director of Vituro and most experienced HIFU urologist in the U.S. to start treating with Ablatherm in September LYON, France , August 31, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company signed a partnership
View HTML
Toggle Summary EDAP TMS to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
LYON, France , August 24, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski , Chief Executive Officer, will present at the 19 th Annual Rodman & Renshaw Global Investment Conference to be held September 10-12, 2017
View HTML
Toggle Summary EDAP TMS Reports Record Second Quarter and First Half 2017 Results
EDAP-TMS Reports Record Second Quarter and First Half 2017 Results Revenue increased 13.7% to a record €9.3 million for the second quarter of 2017 compared to €8.2 million in 2016 HIFU revenue grew 25% when compared to first quarter of 2017 Ablatherm Fusion 510(k) submission completed C-Code
View HTML
Toggle Summary EDAP-TMS to Announce Second Quarter 2017 Financial Results on Wednesday, August 23, 2017
PRESS RELEASE Contact: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 bconfort@edap-tms.com Investors: Rich Cockrell CG CAPITAL 877.889.1972 rich@cg.capital   EDAP-TMS to Announce Second Quarter 2017 Financial Results on Wednesday, August 23, 2017 Conference Call
View HTML
Toggle Summary EDAP Announces filing of 510(k) Application for Ablatherm-Fusion® device
LYON, France , July 31, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a 510(k) application for its Ablatherm Fusion device, enabling a more precise method for targeting of diagnosed areas within the prostate.
View HTML
Toggle Summary EDAP to Host Webcast Discussing HIFU Devices with an American Key Opinion Leader
Webcast to be held Thursday, July 27 th , 2017 LYON, France , July 18, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company plans to host an investor call with commentary from an American robotic surgeon and oncologist to
View HTML